Silver Spring, Maryland, August 13, 2026
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for Simparica TRIO (sarolaner, moxidectin, and pyrantel chewable tablets) to treat New World screwworm (NWS) infestations in dogs and puppies. The regulatory action provides veterinarians with an additional treatment option should dogs become affected by the parasitic infestation. The FDA determined, based on the totality of available scientific evidence, that it is reasonable to believe Simparica TRIO may be effective for treating NWS myiasis when used as authorized and that its known and potential benefits outweigh its known and potential risks. The authorization applies specifically to treatment and does not cover prevention of New World screwworm.
FDA Expands Emergency Treatment Options
New World screwworm is a parasitic infestation caused when screwworm larvae develop in wounds or body openings of affected animals. According to the FDA, most dogs in the United States currently face a low risk of exposure because of their geographic location. However, dogs living in, traveling to, or returning from areas where NWS has been identified by animal-health authorities may face increased risk and should be monitored for signs of infestation. Visible maggots and foul odors from wounds or body openings can be warning signs requiring prompt veterinary attention. The EUA represents an important veterinary regulatory milestone because it allows an already approved animal drug to be used for an additional emergency indication. Simparica TRIO was originally approved by the FDA in 2020 for heartworm, flea, and tick-related indications in dogs and puppies. The new authorization expands its emergency-use role to the treatment of NWS myiasis, giving veterinary professionals another option in the event of infestation.
Simparica TRIO Targets New World Screwworm
Simparica TRIO contains three active ingredients: sarolaner, moxidectin, and pyrantel. Sarolaner belongs to the isoxazoline class of antiparasitic drugs, while the combination product has previously been used for established parasite-related indications in dogs. Under the new EUA, the product can be used for treatment of NWS infestations, but the FDA has not authorized it for preventing future NWS infestations. Because sarolaner and other isoxazoline products have been associated with neurological adverse reactions in some animals, including muscle tremors, loss of coordination, and seizures, Simparica TRIO remains available only by prescription from a licensed veterinarian. The FDA recommends professional veterinary oversight so potential adverse reactions can be appropriately monitored and managed. Dog owners should consult their veterinarian to determine whether the product is appropriate for their animals.
Regulatory Action Supports Veterinary Preparedness
The FDA said the EUA is intended to help ensure that veterinarians and pet owners have multiple treatment options if animals become infested with New World screwworm. The authorization is part of the broader U.S. response to the potential threat posed by NWS, while current U.S. detections remain geographically limited. The EUA will remain effective until it is revoked or until the relevant federal emergency declaration is terminated. Simparica TRIO is sponsored by Zoetis Inc., headquartered in Kalamazoo, Michigan. The FDA’s emergency authorization demonstrates how established veterinary medicines can be evaluated and made available for new uses when emerging animal-health threats create an urgent need for additional treatment options. For veterinary medicine and animal-health researchers, the decision also highlights the importance of regulatory preparedness, evidence-based emergency authorization, parasite control, and veterinary drug safety.
The FDA’s action provides a significant development for the veterinary pharmaceutical sector as authorities continue preparing for potential NWS cases. By applying the available scientific evidence to an established veterinary medicine, the agency has created another potential treatment pathway for affected dogs and puppies while maintaining prescription controls and safety considerations. The authorization therefore represents an important FDA veterinary drug regulatory development and a relevant milestone in efforts to strengthen preparedness against emerging animal-health threats.
Source: FDA press release



